Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation

Blood

Volumn 111, Issue 3, 2008, Pages 1193-1200

  Zhang, Linsheng ^a   Fried, Florence B ^a   Guo, Hong ^a   Friedman, Alan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYCLIN DEPENDENT KINASE; TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE MUTATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

EID: 38949161909     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-109702     Document Type: Article

References (37)

1. Friedman AD. Leukemogenesis by CBF oncoproteins. Oncogene. 1999;13:1932-1942.
2. Bae SC, Yamaguchi-Iwai Y, Ogawa E, et al. Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 1993;8:809-814.
3. Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol. 1993;13:6336-6345.
4. Redondo JM, Pfohl JL, Hernandez-Munain C, Wang S, Speck NA, Krangel MS. Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor δ and murine leukemia virus enhancers. Mol Cell Biol. 1992;12:4817-4823.
5. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid proto-oncogenes AML1 and PEBP2β/CBFβ, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol. 1994;14:5558-5568.
6. Zhang DE, Fujioka KI, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol. 1994;14:8085-8095.
7. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-4341.
8. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
9. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93:3444-3449.
10. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106:494-504.
11. Cao W, Britos-Bray M, Claxton DF, et al. CBFβ-SMMHC, expressed in M4eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene. 1997;15:1315-1327.
12. Cao W, Adya N, Britos-Bray M, Liu PP, Friedman AD. The core binding factor α interaction domain and the smooth muscle myosin heavy chain segment of CBFβ-SMMHC are both required to slow cell proliferation. J Biol Chem. 1998;273:31534-31540.
13. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol. 2001;21:5577-5590.
14. D'Costa J, Chaudhuri S, Civin CI, Friedman AD. CBFβ-SMMHC slows proliferation of primary murine and human myeloid progenitors. Leukemia. 2005;19:921-929.
15. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher FJ III, Friedman AD. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF: a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene. 2000;19:2695-2703.
16. Bernardin F, Yang Y, Civin CI, Friedman AD. cMyc overcomes cell cycle inhibition by CBFβ-SMMHC, a myeloid leukemia oncoprotein. Cancer Biol Ther. 2002;1:494-498.
17. Strom DK, Nip J, Westendorf JJ, et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem. 2000;275:3438-3445.
18. Yang Y, Wang W, Cleaves R, et al. Acceleration of G1 cooperates with CBFβ-SMMHC to induce acute leukemia in mice. Cancer Res. 2002;62:2232-2235.
19. Bernardin F, Yang Y, Cleaves R, et al. TEL-AML1, Expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res. 2002;62:3904-3908.
20. Bernardin-Fried F, Kummalue T, Leijen S, Collector MI, Ravid K, Friedman AD. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem. 2004;279:15678-15687.
21. Biggs JR, Peterson LF, Zhang Y, Kraft AS, Zhang DE. AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol. 2006;26:7420-7429.
22. Finer MH, Dull TJ, Quin L, Farson D, Roberts MR. Kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood. 1994;83:43-50.
23. Paz-Priel I, Cai DH, Wang D, et al. C/EBPα and C/EBPα myeloid oncoproteins induce bcl-2 via interaction of their basic regions with NF-κB p50. Mol Cancer Res. 2005;3:585-596.
24. Moreno S, Nurse P. Substrates for p34cdc2: in vivo veritas? Cell. 1990;18:61:549-551.
25. Kitbayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998;17:2294-3004.
26. Bernardin F, Friedman AD. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene. 2002;21:3247-3252.
27. Tanaka T, Kurokawa M, Ueki K, et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol. 1996;16:3967-3979.
28. Zhang Y, Biggs JR, Kraft AS. Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem. 2004;279:53116-53115.
29. Imai Y, Kurokawa M, Yamaguchi Y, et al. The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol Cell Biol. 2004;24:1033-1043.
30. Wee HJ, Huang G, Shigesada K, Ito Y. Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Reports. 2002;3:967-974.
31. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem. 2006;281:7118-7128.
32. Burke DJ, Church D. Protein synthesis requirements for nuclear division, cytokinesis, and cell separation in Saccharomyces cerevisiae. Mol Cell Biol. 1991;11:3691-3698.
33. Kanno T, Kanno Y, Chen LF, Ogawa E, Kim WY, Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor α subunit revealed in the presence of the β subunit. Mol Cell Biol. 1998;18:2444-2454.
34. Peterson LF, Boyapati A, Ranganathan V, et al. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol. 2005;25:10205-10219.
35. Huang G, Zhang P, Hirai H, et al. PU. 1 is a major downstream target of AML1 (RUNX1) in adult hematopoiesis. Nature Genet. 2008;40:51-60.
36. Hoogenkamp M, Krysinska H, Ingram R, et al. The pu. 1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. Mol Cell Biol. 2007;27:7425-7438.
37. Kagoshima H, Shigesada K, Kohara Y. RUNX regulates stem cell proliferation and differentiation: insights from studies of C. elegans. J Cell Biochem. 2007;100:1119-1130.